Superior cytotoxic potency of mitoxantrone in interaction with DNA: Comparison with that of daunorubicin

Oncology Research

Volumn 8, Issue 2, 1996, Pages 95-100

  Fukushima, Toshihiro ^a   Kawai, Yasukazu ^a   Nakayama, Takashi ^a   Yamauchi, Takahiro ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Imamura, Shin ^a   Kamiya, Ken Ichi ^a   Tsutani, Hiroshi ^a   Ueda, Takanori ^a   Nakamura, Tom ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

daunorubicin; DNA; mitoxantrone

Indexed keywords

ANTILEUKEMIC AGENT; DAUNORUBICIN; DNA; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN HL 60; DNA CLEAVAGE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; LEUKEMIA CELL; POLYMERIZATION; PRIORITY JOURNAL;

EID: 0029867846     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Zee-Cheng, R. K.-Y.; Cheng, C. C. Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. J. Med. Chem. 21: 291-294;1978.
2. Shenkenberg, T. D.; von Hoff, D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 105:67-81; 1986.
3. Larson, R. A.; Daly, K. M.; Choi, K. E.; Han, D. S.; Sinkule, J. A. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J. Clin. Oncol. 5:391-397; 1987.
4. Hiddemann, W.; Kreutzmann, H.; Straif, K.; Ludwig, W. D.; Mertelsmann, R.; Donhuijsen-Ant, R.; Lengfelder, E.; Arlin, Z.; Büchner, T. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744-749; 1987.
5. Ho, A. D.; Lipp, T.; Ehninger, G.; Illiger, H.-J.; Meyer, P.; Freund, M.; Hunstein, W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia an active and well-tolerated regimen. J. Clin. Oncol. 6: 213-217; 1988.
6. Daenen, S.; Löwenberg, B.; Sonneveld, P.; van Putten, W. L. J.; Verhoef, G.; Vérdonck, L. F.; van Veldhoven, M.; Huijgens, P. C. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia 8:6-10; 1994.
7. Johnson, R. K.; Zee-Cheng, R. K.-Y.; Lee, W. W.; Acton, E. M.; Henry, D. W.; Cheng, C. C. Experimental antitumor activity of aminoanthraquinones. Cancer Treat. Rep. 63: 425-439; 1979.
8. Kapuscinski, J.; Darzynkiewicz, Z.; Traganos, F.; Melamed, M. R. Interactions of a new antitumor agent, 1,4dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10- anthracenedione, with nucleic acids. Biochem. Pharmacol. 30:231-240; 1981.
9. Foye, W. O.; Vajragupta, O.; Sengupta, S. K. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio) vinylquinolinium iodides. J. Pharmaceut. Sci. 71: 253-257; 1982.
10. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375; 1989.
11. Nakamura, T. Recent progress in treatment of haematological malignancies. I. Anticancer agents. Nippon Naika Gakkai Zasshi [Journal of Japanese Society of Internal Medicine] 78:753-758; 1989.
12. Arcamone, F.; Penco, S. Relationship of structure to anticancer activity and toxicity in anthracyclines. In: Takeuchi, T.; Notta, K.; Tanaka, N., eds. Antitumor natural products. Tokyo: Japanese Scientific Societies Press; 1989:pp.81-94.
13. Murdock, K. C; Child, R. G.; Fabio, P. F.; Angier, R. B.; Wallace, R. E.; Durr, F. E.; Citarella, R. V. Antitumor agents. 1. l,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. J. Med. Chem. 22:1024-1030; 1979.
14. Wallace, R. E.; Murdock, K. C.; Angier, R. B.; Dürr, F. E. Activity of a novel anthracenedione, 1,4-dihydroxy5,8-bis{ {(2-[(2-hydroxyethyl)amino]ethyl}amino} )9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res. 39:1570-1574; 1979.
15. Miyamoto, H. In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med. Okayama 40:75-81; 1986.
16. Hill, B. T.; Hosking, L. K.; Shellard, S. A.; Whelan, R. D. H. Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro. Cancer Chemother. Pharmacol. 23:140-144; 1989.
17. Kristensen, J.; Jonsson, B.; Sundström, C.; Nygren, P.; Larsson, R. In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. Med. Oncol. Tumor Pharmacother. 9:65-74; 1992.
18. Kaspers, G. J. L.; Veerman, A. J. P.; Pieters, R.; van Zantwijk, L; Klumper, E.; Hählen, K.; de Waal, F. C.; van Wering, E. R. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 8:24-29; 1994.
19. Ando, S; Sasada, M.; Uchino, H.; Kagawa, D.; Ueda, T.; Nakamura, T. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin. J. Jpn. Soc. Cancer Then 21:2343-2355; 1986.
20. Uchida, M.; Ho, D. H. W; Kamiya, K.; Yoshimura, T.; Sasaki, K.; Tsutani, H.; Nakamura, T. Transport and intracellular metabolism of fluorinated pyrimidines in cultured cell lines. In: Mikanagi, K.; Nishioka, K.; Kelley, W. N., eds. Purine and pyrimidine metabolism in man VI. Tokyo: Plenum Press; 1989:pp.321-326.
21. Fukushima, T.; Ueda, T.; Uchida, M.; Nakamura, T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int. J. Hematol. 57:121-130; 1993.
22. Ueda, T.; Kamiya, K.; Urasaki, Y.; Wataya, S.; Kawai, Y.; Tsutani, H.; Sugiyama, M.; Nakamura, T. Clinical pharmacology of l-β-D-arabinofuranosylcytosine-5'stearylphosphate, an orally administered long-acting derivative of low dose 1-β-D-arabinofuranosylcytosine. Cancer Res. 54:109-113; 1994.
23. Fukushima, T; Kawai, Y.; Urasaki, Y; Yoshida, A.; Ueda, T.; Nakamura, T. Influence of idarubicinol on the antileukemic effect of idarubicin. Leukemia Res. 18:943-947; 1994.
24. Chu, G.; Vollrath, D.; Davis, R. W. Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science 234:1582-1585; 1986.
25. Kawamura, M.; Preisler, H. D. A new approach to the detection of DNA damage. Leukemia Res. 13:391-398; 1989.
26. Krishnamoorthy, C. R.; Yen, S. F.; Smith, J. C; Lown, J. W.; Wilson, W. D. Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)]-poly[d(G-C)], and poly [d(A-T)]-poly[d(A-T)]. Biochemistry 25:5933-5940; 1986.
27. Frederick, C. A.; Williams, L. D.; Ughetto, G.; van der Marel, G. A.; van Boom, J. H.; Rich, A.; Wang, A. H.-J. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29: 2538 -2549; 1990.
28. Lown, J. W; Hanstock, C. C. High field 'H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGp CpG)]2. J. Biomol. Struct. Dyn. 2:1097-1106; 1985.
29. George, J. W.; Ghate, S.; Maison, S. W.; Besterman, J. M. Inhibition of DNA helicase u unwinding and ATPase activities by DNA-interacting ligands. J. Biol. Chem. 267:10683-10689; 1992.
30. Smith, P. J.; Morgan, S. A.; Fox, M. E.; Watson, J. V. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem. Pharmacol. 40:2069-2078; 1990
31. Harker, W. G.; Slade, D. L; Drake, F. H.; Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and druginduced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry 30:9953-9961; 1991.
32. Harker, W. G.; Slade, D. L.; Parr, R. L.; Feldhoff, P. W.; Sullivan, D. M.; Holguin, M. H. Alterations in the topoisomerase II a gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II βenzyme in a mitoxantroneresistant HL-60 human leukemia cell line. Cancer Res. 55:1707-1716; 1995.
33. Basra, J.; Wolf, C. R.; Brown, J. R.; Patterson, L. H. Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Des. 1:45-52; 1985.
34. Smith, P. J.; Sykes, H. R.; Fox, M. E.; Furlong, I. J. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res. 52:4000-4008; 1992.
35. Schleyer, E.; Kamischke, A.; Kaufmann, C. C.; Unterhalt, M.; Hiddemann, W. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 8:435-440; 1994.